Ask AI
ProCE Banner Activity

NATALEE: 5-Yr Distant DFS Across Key Subgroups With Ribociclib + NSAI in HR+/HER2- Early Breast Cancer

Conference Coverage
Slideset

The prespecified 5-year analysis of the phase III NATALEE trial showed that adding ribociclib to an NSAI consistently lowers the risk of distant recurrence in patients with HR-positive/HER2-negative early breast cancer.

Released: December 22, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on predictive biomarkers

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with breast cancer
  • Evaluate new data on novel agents and therapeutic approaches for patients with breast cancer